Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Human Polyclonal Lp-PLA2 Primary Antibody for IF (p), IHC (p) - ABIN686722
Rosing, Fobker, Kannenberg, Gunia, DellAquila, Kwiecien, Stypmann, Nofer: Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. in Atherosclerosis 2013
Show all 2 Pubmed References
Human Monoclonal Lp-PLA2 Primary Antibody for ELISA - ABIN563501
Klee, Finlay, McDonald, Attewell, Hebrink, Dyer, Love, Vasmatzis, Li, Beechem, Klee: Bioinformatics methods for prioritizing serum biomarker candidates. in Clinical chemistry 2007
Human Polyclonal Lp-PLA2 Primary Antibody for FACS, IHC (p) - ABIN653776
Bouchareb, Mahmut, Nsaibia, Boulanger, Dahou, Lépine, Laflamme, Hadji, Couture, Trahan, Pagé, Bossé, Pibarot, Scipione, Romagnuolo, Koschinsky, Arseneault, Marette, Mathieu: Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve. in Circulation 2015
Human Polyclonal Lp-PLA2 Primary Antibody for ELISA, WB - ABIN4238414
Moldoveanu, Serban, Marta, Serban, Huica: Lipoprotein-associated phospholipase A2 activity in patients with preserved left ventricular ejection fraction. in Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2011
Polymorphisms in rs1805017 and rs1805018, additional interaction between rs1805017 and smoking, and haplotype containing the rs1805017-H and rs1805018-T alleles were associated with increased CHD (show CHDH Antibodies) risk.
CD163 (show CD163 Antibodies) positive macrophages have roles in lipoprotein-associated phospholipase A2 activity in atherosclerotic plaque
evidence that Lp-PLA2 could predict all-cause mortality and rehospitalization risk among patients with ACS (show PLA2G15 Antibodies) undergoing PCI (show SERPINA5 Antibodies).
the relationship between two variants of apoC1 (show APOC1 Antibodies) and the risk of polycystic ovary syndrome, evaluated the genotypic effects on clinical, hormonal and metabolic indexes and plasma platelet-activating factor acetylhydrolase (PAF-AH) activity, was investigated.
Met117 oxidation caused enhanced flexibility and decreased compactness in oxidized state. PAF (show PAF Antibodies) binding interaction with oxidized protein was mediated only through hydrophobic interactions.
Persistently elevated serum concentrations of Lp-PLA2 were associated with an unfavorable outcome in patients with sepsis.
Resveratrol downregulates Lp-PLA2 expression by inhibiting oxidative stress via SIRT1 (show SIRT1 Antibodies) pathway in the THP-1-derived macrophages.
Elevated Lp-PLA2 mass was associated with all cause-death independently of other risk factors within one year after acute ischemic stroke.
PLA2G7 and PON1 (show PON1 Antibodies) are overexpressed in prostatic neoplasm patients and can be detected early in blood.
A PLA2G7 gene polymorphism determines the plasma levels of lipoprotein-associated phospholipase A2 activity and mass and manifests as a risk factor for atherosclerosis.
The results demonstrated that Lp-PLA2 is associated with triglycerides which may be helpful for understanding the relationship of this protein with cardiovascular disease.
Effect of splenectomy and autologous spleen transplantation on the serum PAF-AH activity and acute-phase response in a porcine model are reported.
observations support a proatherogenic role for Lp-PLA2
Variable gene expression (eg, matrix metalloproteinase-9 (show MMP9 Antibodies), CCL2 (show CCL2 Antibodies) and Lp-PLA(2) mRNAs), both in regard to the arterial bed and duration of disease, was associated with variable plaque development and progression.
The significant correlation between PLA2G7 RNA expression in plaque macrophages and plasma PAFAH activity suggests that the latter is a consequence, rather than a cause of macrophage accumulation.
Resveratrol downregulates Lp-PLA2 expression by inhibiting oxidative stress via SIRT1 (show SIRT1 Antibodies) pathway in a mouse model of chronic inflammation.
Lp-PLA2 augments the inflammatory response after MI and antagonizes healing by disrupting the balance between inflammation and repair.
Plg (show PLG Antibodies) from mouse plasma contains oxPtdPC adducts that are not affected by the action of Lp-PLA(2), suggesting that linkage to Plg (show PLG Antibodies) protects oxPtdPCs from metabolism during their transport in the plasma.
SAA (show SAA1 Antibodies) up-regulates Lp-PLA2 production significantly via a FPRL1/MAPKs./PPAR-gamma (show PPARG Antibodies) signaling pathway.
Deletion of Pla2g7 decreases small intestinal polyp and colon tumor incidence in ApcMin/+ mice.
Macrophage VLDL receptor (show VLDLR Antibodies) promotes PAFAH (show PAFAH1B1 Antibodies) secretion in mother's milk and suppresses systemic inflammation in nursing neonates.
Pla2g7 and Tnfrsf21 (show TNFRSF21 Antibodies) have been identified as genetic susceptibility to influenza genes in mice.
Pla2g7 plays a crucial physiological role in smooth muscle cell differentiation from stem cells, and interactions between Nrf3 (show NFE2L3 Antibodies) and Pla2g7 are essential.
The effects of a specific lp-PLA2 inhibitor on atherosclerosis in ApoE (show APOE Antibodies)-deficient mice and its associated mechanisms, are reported.
Studies designed to evaluate the ability of precursor forms of PAF-AH to mature to fully active proteins indicated that the N-terminal end of human and mouse PAF-AH played important and opposite roles in this process.
The protein encoded by this gene is a secreted enzyme that catalyzes the degradation of platelet-activating factor to biologically inactive products. Defects in this gene are a cause of platelet-activating factor acetylhydrolase deficiency. Two transcript variants encoding the same protein have been found for this gene.
, 2-acetyl-1-alkylglycerophosphocholine esterase
, LDL-associated phospholipase A2
, PAF 2-acylhydrolase
, PAF acetylhydrolase
, group-VIIA phospholipase A2
, lipoprotein-associated phospholipase A2
, platelet-activating factor acetylhydrolase
, group VII phospholipase A2
, plasma PAF acetylhydrolase